No price history available.
Key financial summary
Financials in AUD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | AUDm | 35 | 36 | 38 | 42 | 50 | 51 | N/A | N/A |
| Operating profit | AUDm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net profit | AUDm | -6 | 1 | 1 | -6 | -0 | -1 | N/A | N/A |
| EPS reported | AUD | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating cashflow per share | AUD | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Capex per share | AUD | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF per share | AUD | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Free cash flow | AUDm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt | AUDm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Book value equity | AUDm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Book value per share | AUD | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Number of shares | m | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| DPS (TTM paid) | AUD | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
Financial summary
Financials in AUD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/B LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/S LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/FCF LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EV/EBITDA LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EV/Sales LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Earnings Yield LTM | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF Yield | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Quality | |||||||||
| ROE | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| ROIC | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating margin | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Gross margin | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF/Sales | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Growth and momentum | |||||||||
| EPS Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Sales Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net Income Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating Profit Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Dividend and capital structure | |||||||||
| Dividend Yield | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Dividend Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Payout Ratio | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF/Debt | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net Debt/EBITDA | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EBIT/Net interest | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt/market cap | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt/Equity | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Gross debt/equity | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
Company overview
Compumedics Limited is a global medical technology enterprise engaged in the full lifecycle of designing, producing, marketing, and distributing advanced diagnostic medical devices. Its market reach extends across Australia, the Asia Pacific region, the Americas, Europe, and the Middle East. The company's product portfolio is primarily focused on solutions for sleep and neurological disorders. For sleep diagnostics, offerings include sophisticated PSG:EEG amplification systems like the Grael 4K, portable recording units such as the Somté PSG and Siesta 802, wearable monitoring devices like Somfit/Somfit Pro, and transcutaneous monitors (e.g., TCM5 FLEX). In the field of neurology, Compumedics supplies devices like the ONsight A.V.S. for home ambulatory studies, a variety of EEG amplifiers (e.g., Grael 4K-EEG, Grael LT EEG), comprehensive long-term EEG monitoring systems (Neuvo 64-512 Channel LTM), and specialized EMG/EP systems (including Xegis Forte and Xegis G:NEO). Complementing its hardware, the company develops an extensive range of software, featuring the Profusion Sleep and EEG platforms, Profusion neXus 360 (a web-based system for patient data and lab management), a Multi-Modal Neuroimaging Suite, and workflow optimization tools like Profusion neXus Laboratory Management and Scheduler. Other software offerings include HD Digital Video integration and various specialized applications. Furthermore, Compumedics provides magnetoencephalography systems, cutting-edge brain research technologies, services for pharmaceutical clinical trials and research, as well as a diverse array of accessories and consumables crucial for diagnostic and research endeavors. Established in 1987, Compumedics Limited is based in Abbotsford, Australia, and functions as a subsidiary of D & DJ Burton Holdings Pty Ltd.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
No price history available.
Based on consensus from external analysts. Not Kvantra's opinion.
Compumedics Limited is a global medical technology enterprise engaged in the full lifecycle of designing, producing, marketing, and distributing advanced diagnostic medical devices. Its market reach extends across Australia, the Asia Pacific region, the Americas, Europe, and the Middle East. The company's product portfolio is primarily focused on solutions for sleep and neurological disorders. For sleep diagnostics, offerings include sophisticated PSG:EEG amplification systems like the Grael 4K, portable recording units such as the Somté PSG and Siesta 802, wearable monitoring devices like Somfit/Somfit Pro, and transcutaneous monitors (e.g., TCM5 FLEX). In the field of neurology, Compumedics supplies devices like the ONsight A.V.S. for home ambulatory studies, a variety of EEG amplifiers (e.g., Grael 4K-EEG, Grael LT EEG), comprehensive long-term EEG monitoring systems (Neuvo 64-512 Channel LTM), and specialized EMG/EP systems (including Xegis Forte and Xegis G:NEO). Complementing its hardware, the company develops an extensive range of software, featuring the Profusion Sleep and EEG platforms, Profusion neXus 360 (a web-based system for patient data and lab management), a Multi-Modal Neuroimaging Suite, and workflow optimization tools like Profusion neXus Laboratory Management and Scheduler. Other software offerings include HD Digital Video integration and various specialized applications. Furthermore, Compumedics provides magnetoencephalography systems, cutting-edge brain research technologies, services for pharmaceutical clinical trials and research, as well as a diverse array of accessories and consumables crucial for diagnostic and research endeavors. Established in 1987, Compumedics Limited is based in Abbotsford, Australia, and functions as a subsidiary of D & DJ Burton Holdings Pty Ltd.